DiaGen AI announces Collaboration & Revenue Share Agreement with Hadassah Medical Organization & Ariel University

▤ Summary

DiaGen AI has signed a collaboration and revenue-share agreement with Hadassah Medical Organization and Ariel Scientific Innovations. The partnership will use DiaGen AI’s platform to design and optimize P6-DOTA peptide analogs for oncology imaging and targeted therapy. The work combines AI modeling, peptide synthesis, radiolabeling, and in vivo imaging across a one-year research program. This deal points to commercialization potential in AI-driven drug discovery and creates a pathway for future licensing, research, and partner-led development.

▦ Linked Companies